fda compounding semaglutide news october 2025 issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Diabetes advocacy group discourages use
Description
gastric ulcers, inflammatory bowel disease) liver or kidney disease Pharmacokinetics: poorly absorbed
American Journal of Epidemiology (2013) doi:10.1093/aje/kws448
Post-marketing surveillance will be crucial after approval
Consistency, even during challenging times, is the key to eventual success
With diminished cravings and stronger impulse control, many GLP-1 users experienced fewer relapses, which is an encouraging sign for long-term wellness goals
